Fig. 2
From: Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells
CD62L evaluation in HD and MS patients. a Comparison of different treatments. CD62L evaluation in HD (23, solid square), UT (19, open square), IFNβ (26, solid triangle), GA (26, solid diamond), NTZ (113, solid circle), FTY (23, open triangle) and RTX (18, asterisk) groups. The dotted line displays the tentative threshold (8.46 %), the solid line indicates the mean. b Stratification of NTZ analysis by year of treatment. c The first and second semesters of the first year of treatment. CD62L in the first semester, 1–6 months (15 patients; black square), the second semester, 7–12 months (11 patients; grey square), and in first-line drug-treated patients (52 patients, open diamond). The statistical differences were calculated with the Mann-Whitney U test